Market Closed -
Nasdaq
02:00:01 07/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.145
USD
|
-4.16%
|
|
-10.82%
|
-14.50%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
15.03
|
4.937
|
7.864
|
74.04
|
18.22
|
6.819
|
Enterprise Value (EV)
1 |
9.062
|
1.218
|
5.471
|
63.01
|
6.438
|
4.209
|
P/E ratio
|
-1.26
x
|
-0.41
x
|
-0.79
x
|
-1.42
x
|
-0.54
x
|
-0.43
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-29,24,781
x
|
-2,84,595
x
|
-2,85,659
x
|
EV / FCF
|
-1.59
x
|
-0.4
x
|
-1.39
x
|
-8.09
x
|
-0.57
x
|
-0.54
x
|
FCF Yield
|
-62.7%
|
-250%
|
-71.8%
|
-12.4%
|
-176%
|
-186%
|
Price to Book
|
-792
x
|
-82.3
x
|
-86.8
x
|
-17.1
x
|
-24
x
|
-0.69
x
|
Nbr of stocks (in thousands)
|
2,201
|
3,827
|
11,433
|
652
|
1,311
|
1,692
|
Reference price
2 |
341.5
|
64.50
|
34.39
|
113.5
|
13.90
|
4.030
|
Announcement Date
|
24/09/18
|
09/09/19
|
18/09/20
|
28/09/21
|
27/09/22
|
18/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-21.54
|
-22.62
|
-14.74
|
EBIT
1 |
-11.17
|
-8.398
|
-8.145
|
-21.57
|
-22.68
|
-14.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-11.14
|
-8.048
|
-9.126
|
-38.3
|
-22.66
|
-14.65
|
Net income
1 |
-11.14
|
-8.048
|
-9.126
|
-38.3
|
-22.66
|
-14.65
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-271.2
|
-157.9
|
-43.73
|
-80.17
|
-25.80
|
-9.271
|
Free Cash Flow
1 |
-5.682
|
-3.044
|
-3.926
|
-7.786
|
-11.35
|
-7.82
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/09/18
|
09/09/19
|
18/09/20
|
28/09/21
|
27/09/22
|
18/09/23
|
Fiscal Period: June |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-5.971
|
-5.895
|
-5.358
|
-
|
-3.499
|
-
|
-3.349
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-5.966
|
-5.893
|
-5.356
|
-
|
-3.454
|
-
|
-3.335
|
-
|
Net income
|
-8.43
|
-5.895
|
-5.358
|
-4.596
|
-3.454
|
-3.264
|
-3.337
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-12.50
|
-6.000
|
-5.500
|
-3.500
|
-2.100
|
-1.940
|
-1.950
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
11/02/22
|
13/05/22
|
09/11/22
|
14/02/23
|
11/05/23
|
18/09/23
|
-
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
5.97
|
3.72
|
2.39
|
11
|
11.8
|
2.61
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-5.68
|
-3.04
|
-3.93
|
-7.79
|
-11.3
|
-7.82
|
ROE (net income / shareholders' equity)
|
-185%
|
-217%
|
-818%
|
-706%
|
-203%
|
-234%
|
ROA (Net income/ Total Assets)
|
-93.2%
|
-94.5%
|
-146%
|
-164%
|
-96.1%
|
-92.8%
|
Assets
1 |
11.95
|
8.519
|
6.253
|
23.41
|
23.57
|
15.78
|
Book Value Per Share
2 |
-0.4300
|
-0.7800
|
-0.4000
|
-6.640
|
-0.5800
|
-5.860
|
Cash Flow per Share
2 |
2.600
|
0.9700
|
0.2100
|
16.10
|
8.990
|
0.9100
|
Capex
|
-
|
-
|
-
|
0.01
|
-
|
0.23
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/09/18
|
09/09/19
|
18/09/20
|
28/09/21
|
27/09/22
|
18/09/23
|
|
1st Jan change
|
Capi.
|
---|
| -14.50% | 8.37M | | +9.15% | 105B | | -1.08% | 104B | | +5.79% | 22.94B | | -11.55% | 22.34B | | -7.01% | 19.25B | | -37.08% | 17.08B | | -9.91% | 16.96B | | +7.55% | 14.16B | | +40.04% | 12.63B |
Bio Therapeutic Drugs
|